Senescence plays a role in myotonic dystrophy type 1

Area of Science:

• Cellular and Molecular Biology
• Genetics and Genomics
• Aging Research

Background:

• Myotonic dystrophy type 1 (DM1) is an autosomal dominant disorder causing progressive muscle weakness and multisystem degeneration.
• DM1 phenotypes mimic accelerated aging, but underlying mechanisms are unclear.

Purpose of the Study:

• To investigate the molecular mechanisms linking DM1 to accelerated aging phenotypes.
• To evaluate the therapeutic potential of senolytic compounds in DM1.

Main Methods:

• Transcriptomic analysis of DM1 patient fibroblasts, myoblasts, and blood.
• In vitro serial passage studies and in vivo studies using DM1 mouse and Drosophila models.
• Functional studies of BMI1 and downstream cell cycle regulatory pathways.
• Treatment with senolytic compounds (Quercetin, Dasatinib, Navitoclax).

Main Results:

• DM1 cells exhibit decreased cell cycle activity, impaired DNA damage response, and accumulation of cellular senescence.
• DM1 models show reduced longevity and impaired motor function, consistent with accelerated aging.
• Senolytic drug treatment reversed aging phenotypes in DM1 fibroblasts and Drosophila.

Conclusions:

• Cellular senescence accumulation is a key aspect of DM1 pathophysiology.
• Senolytic compounds demonstrate preclinical efficacy for treating DM1-associated aging phenotypes.